{
    "clinical_study": {
        "@rank": "95781", 
        "acronym": "LIRA-Ramadan\u2122", 
        "arm_group": [
            {
                "arm_group_label": "Metformin + liraglutide", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Metformin + SU", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Africa and Asia. The aim of the trial is to investigate the\n      efficacy and safety of liraglutide versus sulphonylurea (SU) both in combination with\n      metformin during Ramadan in subjects with type 2 diabetes (T2DM)."
        }, 
        "brief_title": "Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects diagnosed with T2DM and treated with metformin equal to or above 1000 mg/day\n             and SU (gliclazide, glipizide or glyburide/glibenclamide at maximum tolerated dose\n             (at least half maximum approved dose) or glimepiride at maximum tolerated dose (at\n             least 2 mg/day)), both at a stable dose for at least 90 days prior to screening.\n             Stable is defined as unchanged medication and dose\n\n          -  HbA1c 7.0-10.0% (53- 86 mmol/mol) (both inclusive)\n\n          -  Body Mass Index (BMI) equal to or above 20 kg/m^2\n\n          -  Subjects who have expressed their intention to fast (daytime, i.e. between sunrise\n             and sunset) during Ramadan after receiving medical counselling regarding the risk of\n             fasting\n\n        Exclusion Criteria:\n\n          -  Any contraindication for successful and sustained fasting from a medical perspective\n             at the discretion of the investigator (such as acute illness, severe hypoglycaemia\n             within 90 days prior to screening, a history of recurrent hypoglycaemia,\n             hypoglycaemia unawareness, ketoacidosis within 90 days prior to screening,\n             hyperosmolar hyperglycaemic coma within 90 days prior to screening, subjects\n             performing intense physical labour)\n\n          -  Any chronic disorder or severe disease which, in the opinion of the investigator\n             might jeopardise subject's safety or compliance with the protocol\n\n          -  History of chronic pancreatitis or idiopathic acute pancreatitis\n\n          -  Screening calcitonin value equal to or above 50 ng/L\n\n          -  Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine\n             neoplasia syndrome type 2 (MEN 2)\n\n          -  Impaired liver function, defined as alanine aminotransferase (ALAT) equal to or above\n             2.5 times upper normal limit (UNL)\n\n          -  Impaired renal function defined as estimated glomerular filtration rate (eGFR) below\n             60 mL/min/1.73 m^2 per Modification of Diet in Renal Disease (MDRD) formula)\n\n          -  Any episode of unstable angina, acute coronary event, cerebral stroke/transient\n             ischemic attack (TIA) or other significant cardiovascular event as judged by the\n             investigator within 90 days prior to screening\n\n          -  Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin\n             cancer or squamous cell skin cancer)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "320", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917656", 
            "org_study_id": "NN2211-3987", 
            "secondary_id": "U1111-1132-9716"
        }, 
        "intervention": [
            {
                "arm_group_label": "Metformin + liraglutide", 
                "description": "1.8 mg administered subcutaneously (s.c., under the skin) once daily", 
                "intervention_name": "liraglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Metformin + liraglutide", 
                    "Metformin + SU"
                ], 
                "description": "Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged", 
                "intervention_name": "metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Metformin + SU", 
                "description": "Subjects will continue on their pre-trial SU tablet treatment, doses unchanged", 
                "intervention_name": "sulfonylurea", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Glucagon-Like Peptide 1"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 2, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oran", 
                        "country": "Algeria", 
                        "zip": "31000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ahmedabad", 
                        "country": "India", 
                        "state": "Gujarat", 
                        "zip": "380007"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel", 
                        "zip": "31096"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beirut", 
                        "country": "Lebanon"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Putrajaya", 
                        "country": "Malaysia", 
                        "zip": "62250"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "state": "Gauteng", 
                        "zip": "1827"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ajman", 
                        "country": "United Arab Emirates", 
                        "zip": "21499"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dubai", 
                        "country": "United Arab Emirates"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dubai", 
                        "country": "United Arab Emirates", 
                        "zip": "4545"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ras Al Khaimah", 
                        "country": "United Arab Emirates", 
                        "zip": "4727"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sharjah", 
                        "country": "United Arab Emirates", 
                        "zip": "3500"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Umm Al Quwain", 
                        "country": "United Arab Emirates", 
                        "zip": "24"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Algeria", 
                "India", 
                "Israel", 
                "Lebanon", 
                "Malaysia", 
                "South Africa", 
                "United Arab Emirates"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Algeria: Ministry of Health", 
                "India: Drugs Controller General of India", 
                "Israel: Ministry of Health", 
                "Lebanon: Ministry of Public Health", 
                "Malaysia: Ministry of Health", 
                "South Africa: Medicines Control Council", 
                "United Arab Emirates: Drug Control Department - Medicines and Pharmacy Control - Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in fructosamine from start of Ramadan to end of Ramadan", 
            "safety_issue": "No", 
            "time_frame": "Day -1, day 29"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917656"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Fructosamine at end of Ramadan", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "measure": "Change from start of Ramadan to end of Ramadan in fasting plasma glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Day -1, day 29"
            }, 
            {
                "measure": "Change from baseline to end of Ramadan in FPG", 
                "safety_issue": "No", 
                "time_frame": "Baseline, day 29"
            }, 
            {
                "measure": "Change from baseline to end of Ramadan in glycosylated haemoglobin (HbA1c)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, day 29"
            }, 
            {
                "measure": "Change from baseline to end of Ramadan in body weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline, day 29"
            }, 
            {
                "measure": "Subjects who at end of treatment (4 weeks post Ramadan) achieve (y/n): HbA1c below 7.0% (53 mmol/mol) (ADA target)", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "measure": "Subjects who at end of treatment (4 weeks post Ramadan) achieve (y/n): HbA1c below 7.0% (53 mmol/mol), and no confirmed hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "measure": "Number of confirmed hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Day -1 to day 29"
            }, 
            {
                "measure": "Number of treatment emergent adverse events (TEAEs)", 
                "safety_issue": "No", 
                "time_frame": "Day -1 to day 29"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}